Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E25.64 EPS (ttm)6.35 Insider Own0.10% Shs Outstand760.67M Perf Week3.25%
Market Cap123.84B Forward P/E17.52 EPS next Y9.29 Insider Trans4.68% Shs Float759.84M Perf Month10.99%
Income4.89B PEG2.48 EPS next Q2.05 Inst Own82.00% Short Float1.43% Perf Quarter21.25%
Sales19.74B P/S6.27 EPS this Y20.30% Inst Trans0.40% Short Ratio2.76 Perf Half Y41.70%
Book/sh33.28 P/B4.89 EPS next Y8.01% ROA7.10% Target Price165.62 Perf Year47.85%
Cash/sh36.91 P/C4.41 EPS next 5Y10.35% ROE20.70% 52W Range106.69 - 164.83 Perf YTD45.48%
Dividend2.44 P/FCF23.20 EPS past 5Y12.00% ROI10.50% 52W High-1.23% Beta0.52
Dividend %1.50% Quick Ratio3.90 Sales past 5Y4.50% Gross Margin80.40% 52W Low52.61% ATR3.68
Employees20000 Current Ratio4.20 Sales Q/Q6.00% Oper. Margin34.90% RSI (14)67.00 Volatility2.22% 1.97%
OptionableYes Debt/Eq1.30 EPS Q/Q-10.10% Profit Margin24.70% Rel Volume0.94 Prev Close162.68
ShortableYes LT Debt/Eq1.20 EarningsOct 27 AMC Payout35.70% Avg Volume3.94M Price162.81
Recom2.30 SMA202.30% SMA5011.02% SMA20028.13% Volume3,703,974 Change0.08%
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Sep-12-12Downgrade Robert W. Baird Outperform → Neutral $84
Sep-10-12Upgrade UBS Neutral → Buy $80 → $96
Nov-22-14 05:00AM  Motley Fool: Pundits pandering your wealth away at USA TODAY
Nov-21-14 04:00PM  Amgen and AbbVie Strengthen Manufacturing Facilities in Asia Zacks
03:30PM  Highlights of activist fund JANA Partners 3Q 13F Market Realist
11:08AM  Loeb wins battle to appoint Dow Chemical directors at Financial Times
06:49AM  Fighting kids' cancer... fixing a broken system CNBC
Nov-20-14 08:14PM  SINGAPORE PRESS-Amgen opens S$200 mln plant in Singapore-Straits Times Reuters
Nov-19-14 10:00PM  Amgen Opens Next-generation Biomanufacturing Facility in Singapore PR Newswire
02:35PM  Will The IMPROVE-IT Results Impact The Thinking Of The FDA And Payers On LDL-Cholesterol Lowering Drugs? at Forbes
11:07AM  Stocks Boosted by Merck's Vytorin Data at Barrons.com
07:50AM  #PreMarket Primer: Wednesday, November 19: Burst Of Cold Creates Chaos In New York Benzinga
Nov-18-14 07:00PM  Amgen Inc Conference Call to Discuss Evolocumab Development Program at AHA scheduled for 7:00 pm ET today CCBN
04:00PM  Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels PR Newswire
Nov-17-14 01:41PM  Long-Awaited Study Boosts Merck, Could Be Good News for Regeneron, Amgen at Barrons.com
01:35PM  Merck Drug Works: Vytorin Study Proves Successful at Investor's Business Daily
12:03PM  3 Stocks Moving The Drugs Industry Upward at TheStreet
11:32AM  IMPROVE-IT Meets Endpoint And Demonstrates Real But Modest Clinical Benefit For Ezetimibe at Forbes
Nov-15-14 07:12PM  At the American Heart Association Meeting You Really Can't Escape The New Cholesterol Drugs at Forbes
Nov-14-14 05:00PM  Biotech correction coming? 16 trades, 55 seconds CNBC
04:15PM  Amgen To Present At The Jefferies Global Healthcare Conference PR Newswire
12:15PM  Window into 13F filings CNBC
11:40AM  Jana Partners takes new stakes in Alibaba, McDonald's in 3rd qtr Reuters
Nov-13-14 06:58PM  Which Health Care ETF Should You Buy? at Investor's Business Daily
04:10PM  AstraZeneca/Amgen's Brodalumab Positive in Psoriasis Trial Zacks
01:25PM  Amgen Shares Consolidating Ahead Of More Gains? Benzinga
12:06PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
10:21AM  A Day Of Reckoning Approaches For Merck And Its Critics at Forbes
07:36AM  The Zacks Analyst Blog Highlights: Dendreon, Amgen, Regeneron, AbbVie and Gilead Zacks
Nov-12-14 04:35PM  Amgen To Webcast Investor Call At Upcoming American Heart Association Scientific Sessions PR Newswire
04:01PM  Amgen To Highlight New Data For Investigational Cholesterol-Lowering Medication Evolocumab PR Newswire
09:17AM  UPDATE: Deutsche Bank Reiterates On Amgen On Potential Of New Drugs Benzinga
09:00AM  The Amgen Foundation Expands Amgen Scholars Program to 17 Top Educational Institutions Worldwide PR Newswire
07:48AM  Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy Zacks
Nov-11-14 04:52PM  Amgen psoriasis drug tops J&J's Stelara in Phase III study Reuters
04:01PM  Amgen And AstraZeneca Announce Positive Results From Second Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
08:31AM  Stock Market News for November 11, 2014 Zacks
Nov-10-14 09:15AM  FDA Accepts Amgen's Biologics License Application For LDL Cholesterol-Lowering Medication Evolocumab PR Newswire
Nov-09-14 03:22PM  Trust Trumps Privacy In Battle For Patient Health Data at Forbes
Nov-07-14 09:57AM  A Few Good Ten in the Nasdaq 100 Yahoo Finance Blogs
Nov-06-14 06:41PM  Top Large-Cap Growth Mutual Funds Defy Gravity at Investor's Business Daily
04:30PM  Amgen To Present At The Credit Suisse Annual Healthcare Conference PR Newswire
04:01PM  Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014 PR Newswire
Nov-05-14 01:04PM  AMGEN INC Financials EDGAR Online Financials
Nov-04-14 12:54PM  Midday movers: Amgen, Ford, Vitamin Shoppe & more at CNBC
09:51AM  [$$] Amgen's Ovarian Cancer Drug Fails To Meet Endpoints at The Wall Street Journal
09:49AM  Amgen ovarian cancer drug fails to improve overall survival Reuters
09:00AM  Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer PR Newswire
Nov-03-14 04:31PM  It was a lackluster trading session for U.S. equities Yahoo Finance Blogs
11:32AM  Amgen and Sandoz Square Off Over a Biosimilar Application at The Wall Street Journal
10:19AM  How hedge funds fared in October CNBC
06:02AM  Activists leading hedge funds warm up for tough season ahead at Financial Times
Nov-01-14 10:00AM  Who are Amgen Inc.'s (AMGN) main competitors? at Investopedia
Oct-31-14 08:08PM  10-Q for Amgen, Inc. Company Spotlight
05:26PM  Today's Market Thorns, Roses, All Time Highs, and ETF All Time Highs Yahoo Finance Blogs
02:58PM  The Untouchables: Where Even Activist Investors Fear to Tread TheStreet
02:25PM  AbbVie Beats Q3 Earnings Estimates, Raises Guidance at Investor's Business Daily
Oct-30-14 05:21PM  Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
08:55AM  Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings at 24/7 Wall St.
Oct-29-14 05:58PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:00PM  Amgens operating margins have been flat despite revenue growth Market Realist
04:47PM  AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:43PM  FOMC: Not necessarily more hawkish, but certainly appeared a bit less dovish Yahoo Finance Blogs
04:22PM  Stocks Trim Losses After Fed Report; Solarwinds Soars at Investor's Business Daily
03:29PM  Why Nomura Upgraded Amgen at Barrons.com
02:53PM  Amgen Up on Strategic Initiatives and 2015 Guidance Zacks
11:28AM  Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Zacks
09:00AM  Third Point Partners ups stake in Amgen Market Realist
Oct-28-14 10:51PM  Amgen, bowing to hedge fund pressure, to cut up to 1,100 more jobs at Los Angeles Times +6.06%
07:09PM  Australian shares hit 6-week peak after US rally; Fed in focus at CNBC
05:58PM  Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:52PM  [video]Stocks Rally Tuesday; Dow Posts Triple-Digit Gain, Topping 17,000 at TheStreet
04:25PM  US STOCKS-Wall St jumps 1 pct, S&P ends above key level Reuters
04:20PM  Amgen has attractive, high-growth assets Market Realist
02:18PM  Amgen Refuses To Split, But Plans Hearten Investors at Investor's Business Daily
01:55PM  Amgen climbs after strong sales figures at Financial Times
01:51PM  How Many? Amgen Rejects a Break Up, But Will Slash Another 1,100 Jobs at The Wall Street Journal
01:45PM  Amgen 2015 outlook tops estimates, no plan to split; shares jump Reuters
01:33PM  Amgen At All-Time High, Deutsche Bank Ups Price Target Benzinga
01:04PM  Health Care Stocks On The Rise With Help From 3 Stocks at TheStreet
12:33PM  Amgen to cut up to 1,100 more jobs at Los Angeles Times
12:24PM  Amgen (AMGN) Stock Is Climbing Today Following Earnings Release at TheStreet
12:04PM  Stocks Extend Gains As Alibaba, Tesla Rally at Investor's Business Daily
11:37AM  Amgen (AMGN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
11:31AM  Amgen CEO: We're not splitting up at CNBC
11:29AM  Stocks gain; Nasdaq, S&P 500 positive for October at CNBC
11:00AM  [$$] Amgen, Under Pressure, Outlines Strategy at The Wall Street Journal
10:36AM  Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing at Investor's Business Daily
10:11AM  Amgen: Cost Cutting, Buybacks and No Split at Barrons.com
09:32AM  Amgen Rallies 3% After Announcing Growth And Capital Plans Benzinga
09:13AM  Amgen CEO: Not planning on split CNBC
09:07AM  Amgen's stock rises after company outlines capital allocation plans at MarketWatch
08:57AM  AMGEN INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities EDGAR Online
08:51AM  Amgen 2015 forecast tops Street view; sees cost cuts, share buyback Reuters
08:50AM  Amgen Starts $2 Billion Share-Repurchase Plan, Raises Dividend at Bloomberg
08:48AM  Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans PR Newswire
08:10AM  Amgen Beats on Q3 Earnings & Revenues, Ups View Again Zacks
06:00AM  Amgen, Sanofi, Ono link with academia on proteins project Reuters
05:00AM  'Fast Money' Recap: Is It Still Worth Investing in Twitter? at TheStreet
12:25AM  Amgen Beats Earnings Estimates, What's Next for AMGN? Zacks
Oct-27-14 07:41PM  Amgen raises forecast as quarterly profit tops estimates at Los Angeles Times
07:00PM  Four Biotechs Lead Health Care Stocks In Big Cap 20 at Investor's Business Daily
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM